Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6

Cancer Letters

Volumn 371, Issue 1, 2016, Pages 134-141

  Fellenberg, Jörg ^a   Sähr, Heiner ^a   Kunz, Pierre ^a   Zhao, Zhefu ^b   Liu, Li ^b   Tichy, Diana ^c   Herr, Ingrid ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Giant cell tumor of bone; Mesenchymal stem cell; MicroRNA; MiR 127 3p; MiR 376a 3p; Neoplastic transformation

Indexed keywords

MICRORNA; MICRORNA 127 3P; MICRORNA 376A 3P; UNCLASSIFIED DRUG; GLE1 PROTEIN, HUMAN; MIRN127 MICRORNA, HUMAN; MIRN376 MICRORNA, HUMAN; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PDIA6 PROTEIN, HUMAN; PROTEIN DISULFIDE ISOMERASE;

ARTICLE; BONE DERIVED STROMAL CELL; CELL MIGRATION; CELL PROLIFERATION; COA1 GENE; COLONY FORMATION; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE TARGETING; GENOME ANALYSIS; GLE1 GENE; LUCIFERASE ASSAY; MOLECULAR PATHOLOGY; ONCOGENE; OSTEOCLASTOMA; PDIA6 GENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; STROMA CELL; TUMOR SPHEROID; BONE TUMOR; CELL MOTION; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TIME FACTOR; TUMOR CELL CULTURE; TUMOR INVASION;

BONE NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; GIANT CELL TUMOR OF BONE; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; PHENOTYPE; PROTEIN DISULFIDE-ISOMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPHEROIDS, CELLULAR; STROMAL CELLS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 84951823375     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.10.039     Document Type: Article

References (39)

1. Gupta R., Seethalakshmi V., Jambhekar N.A., Prabhudesai S., Merchant N., Puri A., et al. Clinicopathologic profile of 470 giant cell tumors of bone from a cancer hospital in western India. Ann. Diagn. Pathol 2008, 12:239-248.
2. Wulling M., Engels C., Jesse N., Werner M., Delling G., Kaiser E. The nature of giant cell tumor of bone. J. Cancer Res. Clin. Oncol 2001, 127:467-474.
3. Balke M., Schremper L., Gebert C., Ahrens H., Streitbuerger A., Koehler G., et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J. Cancer Res. Clin. Oncol 2008, 134:969-978.
4. Viswanathan S., Jambhekar N.A. Metastatic giant cell tumor of bone: are there associated factors and best treatment modalities?. Clin. Orthop. Relat. Res 2010, 468:827-833.
5. Osaka S., Toriyama M., Taira K., Sano S., Saotome K. Analysis of giant cell tumor of bone with pulmonary metastases. Clin. Orthop. Relat. Res 1997, 253-261.
6. Becker W.T., Dohle J., Bernd L., Braun A., Cserhati M., Enderle A., et al. Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy. J. Bone Joint Surg. Am 2008, 90:1060-1067.
7. Capanna R., Fabbri N., Bettelli G. Curettage of giant cell tumor of bone. The effect of surgical technique and adjuvants on local recurrence rate. Chir. Organi Mov 1990, 75:206.
8. Balke M., Campanacci L., Gebert C., Picci P., Gibbons M., Taylor R., et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer 2010, 10:462.
9. Thomas D., Henshaw R., Skubitz K., Chawla S., Staddon A., Blay J.Y., et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 2010, 11:275-280.
10. Wulling M., Delling G., Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum. Pathol 2003, 34:983-993.
11. Byers V.S., Levin A.S., Johnston J.O., Hackett A.J. Quantitative immunofluorescence studies of the tumor antigen-bearing cell in giant cell tumor of bone and osteogenic sarcoma. Cancer Res 1975, 35:2520-2531.
12. Lan J., Liu X., Rong W., Wei F., Jiang L., Yu H., et al. Stro-1(+) stromal cells have stem-like features in giant cell tumor of bone. J. Surg. Oncol 2012, 106:826-836.
13. Liu L., Aleksandrowicz E., Fan P., Schonsiegel F., Zhang Y., Sahr H., et al. Enrichment of c-Met+ tumorigenic stromal cells of giant cell tumor of bone and targeting by cabozantinib. Cell Death Dis 2014, 5:e1471.
14. Ghert M., Simunovic N., Cowan R.W., Colterjohn N., Singh G. Properties of the stromal cell in giant cell tumor of bone. Clin. Orthop. Relat. Res 2007, 459:8-13.
15. Huang L., Teng X.Y., Cheng Y.Y., Lee K.M., Kumta S.M. Expression of preosteoblast markers and Cbfa-1 and Osterix gene transcripts in stromal tumour cells of giant cell tumour of bone. Bone 2004, 34:393-401.
16. Fellenberg J., Saehr H., Lehner B., Depeweg D. A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. Cancer Lett 2012, 321:162-168.
17. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
18. Rehmsmeier M., Steffen P., Hochsmann M., Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004, 10:1507-1517.
19. Robinson D., Segal M., Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology 2002, 70:333-342.
20. Gorunova L., Vult von Steyern F., Storlazzi C.T., Bjerkehagen B., Folleras G., Heim S., et al. Cytogenetic analysis of 101 giant cell tumors of bone: nonrandom patterns of telomeric associations and other structural aberrations. Genes Chromosomes Cancer 2009, 48:583-602.
21. Bridge J.A., Neff J.R., Mouron B.J. Giant cell tumor of bone. Chromosomal analysis of 48 specimens and review of the literature. Cancer Genet. Cytogenet 1992, 58:2-13.
22. Bridge J.A., Neff J.R., Bhatia P.S., Sanger W.G. Cytogenetic analysis of giant cell tumors of bone, diagnostic and prognostic implications. Chir. Organi Mov 1990, 75:187-188.
23. Behjati S., Tarpey P.S., Presneau N., Scheipl S., Pillay N., Van Loo P., et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat. Genet 2013, 45:1479-1482.
24. Chan K.M., Fang D., Gan H., Hashizume R., Yu C., Schroeder M., et al. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013, 27:985-990.
25. Lewis P.W., Muller M.M., Koletsky M.S., Cordero F., Lin S., Banaszynski L.A., et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 2013, 340:857-861.
26. Lehner B., Kunz P., Saehr H., Fellenberg J. Epigenetic silencing of genes and microRNAs within the imprinted Dlk1-Dio3 region at human chromosome 14.32 in giant cell tumor of bone. BMC Cancer 2014, 14:495.
27. Astuti D., Latif F., Wagner K., Gentle D., Cooper W.N., Catchpoole D., et al. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour. Br. J. Cancer 2005, 92:1574-1580.
28. Cheunsuchon P., Zhou Y., Zhang X., Lee H., Chen W., Nakayama Y., et al. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas. Am. J. Pathol 2011, 179:2120-2130.
29. Wang S., Li H., Wang J., Wang D., Yao A., Li Q. Prognostic and biological significance of microRNA-127 expression in human breast cancer. Dis. Markers 2014, 2014. 401986.
30. Guo L.H., Li H., Wang F., Yu J., He J.S. The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int. J. Mol. Sci 2013, 14:14171-14184.
31. Pierrel F., Bestwick M.L., Cobine P.A., Khalimonchuk O., Cricco J.A., Winge D.R. Coa1 links the Mss51 post-translational function to Cox1 cofactor insertion in cytochrome c oxidase assembly. EMBO J. 2007, 26:4335-4346.
32. Morciano P., Carrisi C., Capobianco L., Mannini L., Burgio G., Cestra G., et al. A conserved role for the mitochondrial citrate transporter Sea/SLC25A1 in the maintenance of chromosome integrity. Hum. Mol. Genet 2009, 18:4180-4188.
33. Mo Z.H., Wu X.D., Li S., Fei B.Y., Zhang B. Expression and clinical significance of microRNA-376a in colorectal cancer. Asian Pac. J. Cancer Prev 2014, 15:9523-9527.
34. Formosa A., Markert E.K., Lena A.M., Italiano D., Finazzi-Agro' E., Levine A.J., et al. MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c, miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p, mapped to the 14q32.31 locus, regulate proliferation, apoptosis, migration and invasion in metastatic prostate cancer cells. Oncogene 2014, 33:5173-5182.
35. Zheng Y., Yin L., Chen H., Yang S., Pan C., Lu S., et al. miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett 2012, 586:2396-2403.
36. Zehavi L., Avraham R., Barzilai A., Bar-Ilan D., Navon R., Sidi Y., et al. Silencing of a large microRNA cluster on human chromosome 14q32 in melanoma: biological effects of mir-376a and mir-376c on insulin growth factor 1 receptor. Mol. Cancer 2012, 11:44.
37. Bolger T.A., Folkmann A.W., Tran E.J., Wente S.R. The mRNA export factor Gle1 and inositol hexakisphosphate regulate distinct stages of translation. Cell 2008, 134:624-633.
38. Ramos F.S., Serino L.T., Carvalho C.M., Lima R.S., Urban C.A., Cavalli I.J., et al. PDIA3 and PDIA6 gene expression as an aggressiveness marker in primary ductal breast cancer. Genet. Mol. Res 2015, 14:6960-6967.
39. Tufo G., Jones A.W., Wang Z., Hamelin J., Tajeddine N., Esposti D.D., et al. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ 2014, 21:685-695.